Objectives: Venous limb gangrene has been reported to occur after high warfarin doses in heparin-induced thrombocytopenia (HIT), and this observation has been used to exclude warfarin management in this condition. The outcome of patients receiving modest doses of warfarin was studied. 
H
eparin-induced thrombocytopenia (HIT) is a reaction to heparin that causes platelet activation and thrombosis. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Thrombosis has been attributed to the formation of heparin, platelet factor 4, antibody complexes, endothelial injury, and the release of platelet-derived microparticles that may have procoagulant activity. 12, 13 Warfarin treatment during acute HIT has been associated with the paradoxical development of venous limb gangrene, causing more than half the limb loss attributable to HIT in one center. 14 Among those patients who developed limb gangrene, the international normalized ratio (INR) advanced more rapidly and to higher levels (INR Ͼ 4.0) soon after starting warfarin, possibly contributing to the 12% incidence of venous gangrene among these patients. 15 Rapid loading of warfarin can lead to depletion of anticoagulant vitamin K-dependent protein C faster than it depletes procoagulant vitamin-Kdependent proteins, and its use in HIT has been proscribed in the absence of an antithrombotic agent. 6, 12, 14, 16, 17 In 1991, a database of HIT patients was begun at Loyola University Medical Center to improve the understanding of its clinical, demographic, and laboratory features. During this period, and in the absence of antithrombin agents in all but one patient, warfarin was administered without apparent harm. In the present study, the outcome of HIT patients who received warfarin was reviewed to determine whether there is a "safe" dose of warfarin. Warfarin patients were also compared to the remaining HIT patients who did not receive warfarin to determine if excess thrombotic events occurred with the use of this therapy.
Materials and Methods
A retrospective chart review identified from laboratory records on consecutive hospitalized patients with thrombocytopenia, and a positive heparin-induced platelet aggregation test from January 1991 inclusive to December 1993 (n ϭ 120) provided the data for the present study. This time period was chosen to coincide with a hospital-wide education program on the recognition of HIT. It was stopped when the clinical trials of thrombin inhibitors for this condition began.
Porcine mucosal heparin was used except during cardiopulmonary bypass when bovine lung heparin was used. Baseline platelet counts were defined as the highest platelet count occurring any time prior to the platelet decline. The onset of thrombocytopenia was defined from the time when platelets declined to Ͻ 50% of baseline or fell to Ͻ 100 ϫ 10 3 /L. 2 A nadir platelet count was defined as the lowest recorded platelet count. Platelet recovery time was defined as the number of days until platelet counts returned to baseline after heparin cessation. Thrombosis was documented by the following: (1) visible signs of extremity gangrene or tissue necrosis; (2) morphologic, cardiac enzymatic, or angiographic evidence of arterial or venous thrombosis; (3) radiologic findings consistent with tissue infarction; (4) a high probability ventilation-perfusion lung scan indicating pulmonary embolus; or (5) a positive venous Doppler imaging study indicating a deep venous thrombosis. Patients were observed throughout the entire length of stay for thrombosis until discharge or death.
Platelet Aggregation Assay
Heparin-induced platelet aggregation was performed in patients suspected of HIT according to established methods. 4 A Ն 20% change in platelet aggregation as measured by increased light transmission in the heparin mixture indicated a positive result.
Clinical Information
Age, gender, surgical procedures, length of hospital stay, method of heparin delivery, maximum and nadir platelet counts, and the platelet count when warfarin was started were charted. The diagnosis of HIT was made on the date that platelet aggregometry became positive and heparin cessation was ordered for suspected HIT. The time to heparin cessation was defined from the day the platelets fell Ͻ 50% of baseline or an absolute platelet count Ͻ 100 ϫ10 3 /L, whichever came first. The INR during this period was obtained using an international sensitivity index of 2.8. Daily prothrombin times (PTs) were obtained in all patients who received warfarin. Analyzed data included treatment other than heparin cessation, the number of days and doses of warfarin before and after the diagnosis of HIT, final and maximum levels of anticoagulation, days in therapeutic range, and thrombosis while receiving warfarin.
Anticoagulation Regimen
Cardiopulmonary bypass patients undergoing open heart surgery during the study period received 20,000 to 30,000 U of IV heparin to achieve an activated clotting time Ͼ 400 s at the onset of surgery. Enteric-coated aspirin, 325 mg qd, was administered beginning 12 h postoperatively in addition to subcutaneous heparin, 5,000 U bid, until discharge, which was applied to all patients who were not started on IV heparin.
Patients undergoing valve replacement, valvular repair, ventriculotomy, or any other condition requiring long-term anticoagulation received continuous IV heparin, 500 U/h, beginning 24 h postoperatively. This heparin regimen was increased from 100 to 200 U/h/d, but seldom was Ͼ 1,000 U/h based on protocols developed by the cardiovascular and thoracic surgeons. A therapeutic activated partial thromboplastin time (activated partial thromboplastin time ratio, Ն 1.5) was seldom achieved. Heparin-coated Swan-Ganz catheters were used on all patients until hemodynamic stability occurred. Heparin flush solutions at 2 U/mL were used for all arterial lines, central lines, and central catheters.
Noncardiac surgical patients received heparin either as flush solutions; subcutaneously at 5,000 U bid; IV beginning at 1,000 U/h; or with heparin-coated Swan-Ganz catheters.
Statistical Analysis
Statistical analysis was performed using appropriate software (SPSS 8.0 for Windows; SPSS; Chicago, IL). Data were expressed as mean Ϯ SEM. Student's t test for independent samples and Fisher's Exact Test were used to compare nonparametric and numerical data. All p values were two-tailed and statistically significant at Յ 0.05.
Results

Clinical and Laboratory Data
One hundred twenty patients with thrombocytopenia were identified by a positive platelet aggregation test for heparin antibodies. Six patients were excluded for the following reasons: incomplete medical records (four patients), failure to discontinue heparin (one patient), and liver failure (one patient). Therefore, charts from 114 patient were available for review. The mean age of the patients was 64 Ϯ 1 years, and 56% were male. The mean length of hospital stay was 31 Ϯ 3 days (Table 1) . Eighty-nine percent of the patients were recruited from surgical services. Open heart surgery accounted for 59% of the study population, and the remaining surgical patients were recovering from trauma (general, peripheral, and neurosurgery). Nonsurgical patients (11%) had a variety of illnesses, including malignancy, connective tissue diseases, and cardiac diseases.
All patients had received some form of heparin prior to the onset of thrombocytopenia: 70 patients (61%) received at least one bolus dose of IV heparin, 34 patients (30%) received subcutaneous unfractionated heparin, and the remaining received flush injections of heparinized saline solution. Platelet counts decreased to 54 ϫ 10 3 /L or 22 Ϯ 1% of baseline values. Complete platelet recovery occurred in 74 patients (65%) 6.9 Ϯ 0.4 days following heparin discontinuation, and 40 patients (35%) either died or were discharged before complete platelet recovery could be verified. The mean time to heparin cessation was 3.2 Ϯ 0.3 days from the onset of thrombocytopenia. One or more thrombotic complications occurred among 43 patients (38%) and were predominately venous. Venous thrombosis was found at axillary, femoral, iliac, internal jugular, and subclavian sites, with pulmonary embolism occurring in 16 patients. Arterial events included coronary artery or saphenous vein bypass graft occlusion leading to myocardial infarction, vascular compromise causing limb necrosis and amputation, cerebrovascular events, and visceral infarction. Twenty-two patients received a variety of treatment strategies in addition to heparin cessation alone, including thrombolytics (4 patients), plasmapheresis (3 patients), dextran (17 patients), ␥-globulin (1 patient), low molecular weight heparin (1 patient), hiruden (1 patient), hirulog (1 patient), and danaparoid (1 patient). Mortality in the entire cohort was 27%.
Warfarin Patients
Fifty-one patients received or continued warfarin following the diagnosis of HIT. Warfarin was given to 35 patients for indications unrelated to HIT, and to 16 patients for heparin-associated thrombosis (Table 2) Thrombosis occurred in 23 patients (45%), of whom 6 patients (25%) developed a newly recognized thrombus after warfarin was started. This included pulmonary embolism and right femoral artery occlusion after a single dose of warfarin; cerebrovascular accident after 6 days of warfarin in a patient with atrial fibrillation; deep venous thrombosis following two doses of warfarin; left atrial clot by echocardiogram after three doses of warfarin; a transient ischemic attack after two doses of warfarin, and deep venous thrombosis after three doses of warfarin while receiving therapeutic levels of hiruden. Venous gangrene did not occur. Excluding the patient who received hiruden, the mean PT at the time of thrombosis in five patients was 17.0 Ϯ 2.5 s.
Warfarin vs no Warfarin Patients
Fifty-one patients who received warfarin were compared to HIT patients who did not receive warfarin (Table 3) . No differences were found in age, gender, hospital length of stay, platelet decline or recovery, or thrombosis. Differences between groups were found in the number of patients receiving IV heparin (86% vs 41%; p Ͻ 0.001), open heart surgery (78% vs 43%; p Ͻ 0.001), and mortality (8% vs 43%; p Ͻ 0.001). Warfarin patients were also more likely to receive diverse treatment strategies in CHEST / 116 / 0 / 000, 1999 addition to heparin cessation alone (28% vs 13%; p Ͻ 0.001). While time to thrombosis from the onset of thrombocytopenia was shorter in patients receiving warfarin (Fig 1; 4. 7 Ϯ 1.6 days vs 8.7 Ϯ 2.3 days), this was not significant (p ϭ 0.167).
Discussion
HIT is an intensely prothrombotic state, associated with a mortality of 25 to 37% and an equal or greater morbidity due to arterial and venous thrombosis in 30%. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Heparin-induced platelet antibodies can be detected in 8 to 13% of patients receiving unfractionated heparin, with thrombocytopenia developing in approximately 2 to 3%. 18, 19 Thrombosis has been ascribed to heparin and platelet factor 4 complexes that form on the platelet surface and provide a site for antibody binding with subsequent platelet activation and release of platelet-derived prothrombotic microparticles. 12,20 -24 The common clinical practice of initiating warfarin therapy with a relatively high "loading" dose for rapid anticoagulation may be particularly dangerous in this condition. 14, 25 Warkentin et al 14 first reported that warfarin administration during acute HIT was associated with thrombosis that was predominately due to venous gangrene, accounting for more than half of all limb amputations in their series, or 12% of patients who received warfarin. The anticoagulant effect of warfarin was greater in the patients with venous limb gangrene than the remaining warfarin patients who did not develop gangrene (INR, 5.8 vs 3.1, respectively). Plasma from patients with venous limb gangrene had a higher ratio of thrombinantithrombin complex to protein C activity during warfarin treatment. Harrison et al 16 demonstrated that a smaller warfarin dose avoided the development of a potential hypercoagulable state caused by precipitous decreases in levels of protein C. Higher warfarin doses did lead to a more rapid increase in INR, but this was entirely caused by the earlier reduction of factor VII rather than a reduction in factor II, a coagulation protein with a much longer half-life.
In this study, death and thrombosis were not associated with warfarin administration. While six new thrombotic events occurred after warfarin administration, thrombosis may have preceded warfarin use but became clinically manifest after warfarin use. Venous gangrene was not precipitated by the use of warfarin with or without a heparin "overlap" in this study. Compared to study of Warkentin et al, 14 the mean dose of warfarin in the treated patients appeared to be lower and was begun 3 days after the diagnosis of HIT in more than half of patients. Platelets were on the rise, as evidenced by a higher mean platelet count, compared to nadir platelet count when warfarin was started. Fifty-five percent of patients were within minimal therapeutic range (INR Ͼ 2.0), compared to 34 to 61% in randomized trials of warfarin in atrial fibrillation, in clinical practice, and in anticoagulation clinics. 26 -28 Patients who were selected for warfarin therapy were more likely to have received IV heparin, to have undergone cardiac surgery, or to have received treatment other than heparin cessation alone. De- spite these baseline differences, there was an equivalent incidence of thrombosis compared to patients who did not receive warfarin. As warfarin patients were more likely to survive hospitalization, factors other than a clinically recognized thrombosis may have contributed to fatal events. In the absence of serial objective tests, the presence of undiagnosed thrombosis cannot be excluded. Better outcome may have been due to the selection of a healthier population who did not have contraindications to anticoagulation or to other confounding variables that were not investigated in the present study. In the presence of such baseline differences, no statement can be made about the impact of warfarin on survival, but it is reasonable to conclude that warfarin patients did not fare worse. Direct thrombin inhibitors such as recombinant hiruden, an antithrombin produced by the leech, Hirudo medicinalis, appear to be promising in the treatment of HIT. 17, 29, 30 These agents may not be appropriate for all patients with HIT, however, and warfarin still needs to be considered as an option for patients who require anticoagulation. Hiruden is relatively contraindicated in patients with renal insufficiency. It is unclear whether thrombin inhibitors are indicated in patients with HIT who have not developed thrombosis. 17 There may be difficulties in drug titration and monitoring with the use of thrombin inhibitors when combined with warfarin. All clot-based anticoagulation assays are affected by thrombin inhibitors with dramatic interference when both warfarin and thrombin inhibitors are present in plasma. 31 The monitoring of anticoagulation while on a thrombin inhibitor and warfarin has not been standardized, and the clinical relevance of assay values to bleeding and treatment target values need to be determined. 31 If there is thrombosis, however, a thrombin inhibitor should be considered prior to warfarin administration. 6, 17 
Limitations of the Study
This study consisted of patients with a diagnosis of HIT made by platelet aggregometry. Platelet aggregometry, while specific for HIT, has sensitivity that may vary with the performance of the assay. 2 Patients with HIT and a false-negative platelet aggregation test were thus not included in this retrospective study. This study may have underestimated the incidence of thrombotic complications by categorizing only those patients in whom thrombosis was verifiable. While this study reports one of the largest series of patients involving HIT patients, it is not randomized, and is underpowered to detect small differences between groups.
Conclusion
In contrast to previous reports, our study did not show an increased incidence of venous gangrene with low or moderate doses of warfarin. In the absence of an antithrombin agent, small initial doses of warfarin should be administered after platelets begin to rise with careful titration so that the INR does not exceed therapeutic levels. Prospective or larger trials are needed to confirm these findings.
